Mark Pollack to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Mark Pollack has written about Programmed Cell Death 1 Receptor.
Connection Strength
0.603
-
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018 01 01; 29(1):250-255.
Score: 0.603